Taken together, TRZ attenuates the detrimental effects of T2D and obesity on the development and progression of AD by mitigating chronic hyperglycemia in T2D and reducing body weight in obesity
Unlike low-touch programs, patients receive: Consistent communication with a licensed provider Flexible telehealth appointments Support for microdosing when appropriate Personalized treatment plans that evolve with progress Learn more about available programs here: GLP-1 Weight Loss Plans Why Provider-Led GLP-1 Care Matters GLP-1 medications like Semaglutide and Tirzepatide are powerful tools but results depend heavily on proper guidance
Most patients can resume their weight loss trajectory once regular dosing resumes
The SURMOUNT-4 trial data shows that stopping tirzepatide entirely leads to significant weight regain, so maintaining some level of medication support, even at reduced doses, appears to produce better long-term outcomes than complete cessation
Certain clinical situations warrant complete alcohol abstinence for patients taking tirzepatide
In the case of Direct Meds, the company partners with 503A compounding pharmacies that prepare semaglutide and tirzepatide formulations
